x
CME-Tagline

Breaking the Burden: Assessing and Improving Quality of Life in Patients with CRSwNP

CMEO Snack

Premiere Date: Friday, April 22, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Saturday, April 22, 2023

Faculty


Joseph K. Han, MD, FARS, FAAAAI Joseph K. Han, MD, FARS, FAAAAI (Moderator)
Professor
Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, VA
ARS, Immediate Past President
AAAAI, RROAC, Chair

Stella Lee, MD Stella Lee, MD 
Section Chief, Rhinology
Division of Otolaryngology-Head & Neck Surgery
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Statement of Need

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease characterized by rhinosinusitis and the development of polyposis originating in the sinus and eventually extending to the nose. Persistent symptoms include congestion, stuffiness, nasal discharge, facial pain and/or pressure, impairment, or loss of sense of smell, and fatigue. CRSwNP confers a substantial but often underappreciated burden, negatively impacting mental and physical health-related quality of life (HRQoL) endpoints. To help alleviate this burden clinicians need to recognize the impact of CRSwNP and its many comorbidities on patients’ HRQoL and understand how the severity of CRSwNP can affect treatment response and duration.

In part one of this CMEO Snack series on CRSwNP, join Dr. Han and Dr. Lee as they discuss strategies for how clinicians can better recognize and understand the impact of the burden posed by CRSwNP.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the burden of CRSwNP and the impact of this disease on patients' HRQoL and treatment response.

Financial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

UEMS-EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Han reports the following financial relationships:

Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme

Dr. Lee reports the following financial relationships:

Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Janan Sarwar, PharmD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    SN-161-042222-90